TWI388568B - 抗ｆｇｆ１９抗體及其使用方法 - Google Patents

抗ｆｇｆ１９抗體及其使用方法 Download PDF

Info

Publication number
TWI388568B
TWI388568B TW096104900A TW96104900A TWI388568B TW I388568 B TWI388568 B TW I388568B TW 096104900 A TW096104900 A TW 096104900A TW 96104900 A TW96104900 A TW 96104900A TW I388568 B TWI388568 B TW I388568B
Authority
TW
Taiwan
Prior art keywords
antibody
fgf19
cancer
cell
antibodies
Prior art date
Application number
TW096104900A
Other languages
English (en)
Chinese (zh)
Other versions
TW200808827A (en
Inventor
Luc Desnoyers
Dorothy French
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of TW200808827A publication Critical patent/TW200808827A/zh
Application granted granted Critical
Publication of TWI388568B publication Critical patent/TWI388568B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW096104900A 2006-02-10 2007-02-09 抗ｆｇｆ１９抗體及其使用方法 TWI388568B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77231006P 2006-02-10 2006-02-10
US78060806P 2006-03-09 2006-03-09
US88586607P 2007-01-19 2007-01-19

Publications (2)

Publication Number Publication Date
TW200808827A TW200808827A (en) 2008-02-16
TWI388568B true TWI388568B (zh) 2013-03-11

Family

ID=38723925

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096104900A TWI388568B (zh) 2006-02-10 2007-02-09 抗ｆｇｆ１９抗體及其使用方法

Country Status (10)

Country Link
US (4) US7678373B2 (https=)
EP (1) EP1989230B1 (https=)
JP (1) JP5209505B2 (https=)
AR (1) AR059432A1 (https=)
AU (1) AU2007254005B2 (https=)
CA (1) CA2637988A1 (https=)
ES (1) ES2582652T3 (https=)
NZ (1) NZ569957A (https=)
TW (1) TWI388568B (https=)
WO (1) WO2007136893A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1910542B1 (en) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
EP1989230B1 (en) 2006-02-10 2016-06-01 Genentech, Inc. Anti-fgf19 antibodies and methods using same
US20100267145A1 (en) * 2006-06-05 2010-10-21 Hiroshima University Immunocompetent cell having anti-cd38 antibody on its cell surface
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
SI2550972T1 (en) * 2007-04-02 2018-05-31 Genentech, Inc. A Klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
NZ582619A (en) 2007-08-03 2012-08-31 Genentech Inc Humanized anti-fgf19 antagonists and methods using same
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
US20090226459A1 (en) * 2008-01-29 2009-09-10 Cold Spring Harbor Laboratory Role of fgf-19 in cancer diagnosis and treatment
CN102056939A (zh) * 2008-04-30 2011-05-11 温特研究公司 雌激素受体-α的活性的恢复
WO2010008726A1 (en) 2008-06-16 2010-01-21 Immunogen Inc. Novel synergistic effects
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
WO2010006214A1 (en) * 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
MX368790B (es) * 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
AU2010319327B2 (en) 2009-11-13 2015-08-13 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
EP2507381A4 (en) * 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
JP4881428B2 (ja) * 2009-12-25 2012-02-22 株式会社東芝 電子機器
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
KR20190107761A (ko) 2011-03-09 2019-09-20 셀 시그널링 테크놀러지, 인크. 모노클로날 항체를 생성하는 방법 및 시약
WO2012177481A2 (en) * 2011-06-24 2012-12-27 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
JP2015505818A (ja) 2011-11-14 2015-02-26 ファイブ プライム セラピューティックス インコーポレイテッド 癌を治療する方法
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US20130183294A1 (en) * 2012-01-18 2013-07-18 Genentech, Inc. Methods of using fgf19 modulators
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
WO2014075788A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
WO2015092021A1 (en) * 2013-12-20 2015-06-25 Spingotec Therapeutics Gmbh Adrenomedullin binder for use in therapy of cancer
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
JP6585167B2 (ja) 2014-10-03 2019-10-02 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
CN114129709A (zh) * 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
RU2017134379A (ru) 2015-03-25 2019-04-03 Новартис Аг Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4
ES2972458T3 (es) * 2016-02-10 2024-06-12 Bioinvent Int Ab Combinación de anticuerpo humano anti-FGFR4 y sorafenib
EP3453392B1 (en) * 2016-05-17 2025-10-22 Japanese Foundation For Cancer Research Therapeutic agent for lung cancer that has acquired egfr-tki resistance
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
SG11201903911UA (en) 2016-11-02 2019-05-30 Novartis Ag Combinations of fgfr4 inhibitors and bile acid sequestrants
US20190218285A1 (en) * 2018-01-18 2019-07-18 Molecular Cloning Laboratories (MCLAB) LLC Long-Acting Therapeutic Fusion Proteins
CN109251983B (zh) * 2018-08-15 2022-03-25 深圳市罗湖区人民医院 Frs2基因的拷贝数扩增及其应用、检测拷贝数扩增的特异性引物对
EP3873519A1 (en) 2018-10-29 2021-09-08 F. Hoffmann-La Roche AG Antibody formulation
JP7643727B2 (ja) * 2019-02-02 2025-03-11 華輝安健(北京)生物科技有限公司 抗－ｆｇｆ１９抗体
FI3865155T3 (fi) * 2020-02-13 2023-01-13 Menetelmä vasta-aineen kohdespesifiseksi modifioimiseksi
CN116726005B (zh) * 2022-03-03 2026-02-13 上海市第六人民医院 一种治疗运动损伤的药物及筛选方法和应用
JP2025517398A (ja) 2022-05-19 2025-06-05 タイラ・バイオサイエンシーズ・インコーポレイテッド Ｐｐａｒアゴニスト及びｆｇｆｒ４阻害剤による治療
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US20020042367A1 (en) 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20020012961A1 (en) 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
EP1032668B1 (en) 1997-11-25 2008-05-28 Genentech, Inc. Fibroblast growth factor-19
US20050026832A1 (en) 1997-11-25 2005-02-03 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20020155543A1 (en) 1997-11-25 2002-10-24 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20040126852A1 (en) 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
CN1560249A (zh) 1999-09-08 2005-01-05 杰南技术公司 成纤维细胞生长因子-19（fgf-19）的核酸和多肽以及用于治疗肥胖的方法
US7348162B2 (en) 2000-03-22 2008-03-25 Amgen Inc. Nucleic acids encoding fibroblast growth factor receptor-like proteins and uses thereof
US20030143539A1 (en) 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
CA2459219A1 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20030157082A1 (en) 2002-01-31 2003-08-21 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
MXPA04012243A (es) 2002-06-07 2005-02-25 Genentech Inc Composiciones y metodos para l diagnostico y tratamiento de tumores.
US20050198642A1 (en) * 2004-03-04 2005-09-08 International Business Machines Corporation Mechanism for assigning home nodes to newly created threads
US7837626B2 (en) * 2005-08-05 2010-11-23 Siemens Medical Solutions Usa, Inc. Contrast agent manipulation with medical ultrasound imaging
EP1989230B1 (en) * 2006-02-10 2016-06-01 Genentech, Inc. Anti-fgf19 antibodies and methods using same

Also Published As

Publication number Publication date
CA2637988A1 (en) 2007-11-29
ES2582652T3 (es) 2016-09-14
US20120128675A1 (en) 2012-05-24
US20110086032A1 (en) 2011-04-14
US8293241B2 (en) 2012-10-23
US7678373B2 (en) 2010-03-16
JP5209505B2 (ja) 2013-06-12
AU2007254005B2 (en) 2012-11-29
HK1120273A1 (zh) 2009-03-27
WO2007136893A3 (en) 2008-05-15
US8241633B2 (en) 2012-08-14
AU2007254005A1 (en) 2007-11-29
US20070248604A1 (en) 2007-10-25
WO2007136893A2 (en) 2007-11-29
US7846691B2 (en) 2010-12-07
EP1989230A2 (en) 2008-11-12
AR059432A1 (es) 2008-04-09
NZ569957A (en) 2012-03-30
TW200808827A (en) 2008-02-16
EP1989230B1 (en) 2016-06-01
US20100129381A1 (en) 2010-05-27
JP2009525764A (ja) 2009-07-16

Similar Documents

Publication Publication Date Title
TWI388568B (zh) 抗ｆｇｆ１９抗體及其使用方法
US20220089780A1 (en) Klotho beta
CA2693852C (en) Humanized anti-fgf19 antagonists and methods using same
TWI478938B (zh) 抗-ｅｐｈｒｉｎｂ２抗體及使用該抗體的方法
AU2014203654B2 (en) Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
HK1260779A1 (en) A klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
HK1120273B (en) Anti-fgf19 antibodies and methods using same
HK1178787A (en) A klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
HK1178787B (en) A klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees